(11)C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy
Bashari, W. A.
van der Meulen, M.
Powlson, A. S.
Brooke, A. M.
Scoffings, D. J.
O'Donovan, D. G.
Cheow, H. K.
Mendichovszky, I. A.
Kolias, A. G.
Rights© 2022. The Author(s).
MetadataShow full item record
PURPOSE: To assess the potential for (11)C-methionine PET (Met-PET) coregistered with volumetric magnetic resonance imaging (Met-PET/MR(CR)) to inform clinical decision making in patients with poorly visualized or occult microprolactinomas and dopamine agonist intolerance or resistance. PATIENTS AND METHODS: Thirteen patients with pituitary microprolactinomas, and who were intolerant (n = 11) or resistant (n = 2) to dopamine agonist therapy, were referred to our specialist pituitary centre for Met-PET/MR(CR) between 2016 and 2020. All patients had persistent hyperprolactinemia and were being considered for surgical intervention, but standard clinical MRI had shown either no visible adenoma or equivocal appearances. RESULTS: In all 13 patients Met-PET/MR(CR) demonstrated a single focus of avid tracer uptake. This was localized either to the right or left side of the sella in 12 subjects. In one patient, who had previously undergone surgery for a left-sided adenoma, recurrent tumor was unexpectedly identified in the left cavernous sinus. Five patients underwent endoscopic transsphenoidal selective adenomectomy, with subsequent complete remission of hyperprolactinaemia and normalization of other pituitary function; three patients are awaiting surgery. In the patient with inoperable cavernous sinus disease PET-guided stereotactic radiosurgery (SRS) was performed with subsequent near-normalization of serum prolactin. Two patients elected for a further trial of medical therapy, while two declined surgery or radiotherapy and chose to remain off medical treatment. CONCLUSIONS: In patients with dopamine agonist intolerance or resistance, and indeterminate pituitary MRI, molecular (functional) imaging with Met-PET/MR(CR) can allow precise localization of a microprolactinoma to facilitate selective surgical adenomectomy or SRS.
CitationPituitary. 2022 Aug;25(4):573-586. doi: 10.1007/s11102-022-01229-9. Epub 2022 May 24.
NoteRD&E staff can access the full-text of this article by clicking on the 'Additional Link' above and logging in with NHS OpenAthens if prompted.
Showing items related by title, author, creator and subject.
The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders. Henley, W. E.; Anderson, L. J.; Wyatt, K. M.; Nikolaou, V.; Anderson, R.; Logan, Stuart (Springer, 2014-11)Lysosomal storage disorders (LSDs) comprise more than 50 extremely rare, inherited metabolic diseases resulting from a deficiency of specific lysosomal enzymes required for normal macromolecular metabolism. The National ...
Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial. Clarke, Carl E; Patel, Smitaa; Ives, Natalie; Rick, Caroline E; Dowling, Francis; Woolley, Rebecca; Wheatley, Keith; Walker, Marion F; Sackley, Catherine M; PD REHAB Collaborative Group incl:; Butler, Lisa; Elliott, Ruth; Havlin, Fiona; Harrower, Timothy; Holman, Jane; Irvine, Sarah; James, Rob; Lane, Robert; Malone, Timothy; Matthews, Victoria; Pearce, Vaughan R; Potter, Alison; Sheridan, Ray; Smith, Christopher; Woodger, Alan (JAMA, 2016-01-19)It is unclear whether physiotherapy and occupational therapy are clinically effective and cost-effective in Parkinson disease (PD).
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study Chanchlani, N.; Lin, S.; Auth, M. K.; Lee, C. L.; Robbins, H.; Looi, S.; Murugesan, S. V.; Riley, T.; Preston, C.; Stephenson, S.; Cardozo, W.; Sonwalkar, S. A.; Allah-Ditta, M.; Mansfield, L.; Durai, D.; Baker, M.; London, I.; London, E.; Gupta, S.; Di Mambro, A.; Murphy, A.; Gaynor, E.; Jones, K. D. J.; Claridge, A.; Sebastian, S.; Ramachandran, S.; Selinger, C. P.; Borg-Bartolo, S. P.; Knight, P.; Sprakes, M. B.; Burton, J.; Kane, P.; Lupton, S.; Fletcher, A.; Gaya, D. R.; Colbert, R.; Seenan, J. P.; MacDonald, J.; Lynch, L.; McLachlan, I.; Shields, S.; Hansen, R.; Gervais, L.; Jere, M.; Akhtar, M.; Black, K.; Henderson, P.; Russell, R. K.; Lees, C. W.; Derikx, Laap; Lockett, M.; Betteridge, F.; De Silva, A.; Hussenbux, A.; Beckly, J.; Bendall, O.; Hart, J. W.; Thomas, A.; Hamilton, B.; Gordon, C.; Chee, D.; McDonald, T. J.; Nice, R.; Parkinson, M.; Gardner-Thorpe, H.; Butterworth, J. R.; Javed, A.; Al-Shakhshir, S.; Yadagiri, R.; Maher, S.; Pollok, R. C. G.; Ng, T.; Appiahene, P.; Donovan, F.; Lok, J.; Chandy, R.; Jagdish, R.; Baig, D.; Mahmood, Z.; Marsh, L.; Moss, A.; Abdulgader, A.; Kitchin, A.; Walker, G. J.; George, B.; Lim, Y. H.; Gulliver, J.; Bloom, S.; Theaker, H.; Carlson, S.; Cummings, J. R. F.; Livingstone, R.; Beale, A.; Carter, J. O.; Bell, A.; Coulter, A.; Snook, J.; Stone, H.; Kennedy, N. A.; Goodhand, J. R.; Ahmad, T. (Wiley, 2022-08-29)BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD). AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would ...